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ABSTRACT 
Objective: In this study, we attempted to uncover the functional impact of miR-22 
and its target gene in smooth muscle cell (SMC) differentiation, and delineate the 
molecular mechanism involved. 
Approach and Results: miR-22 was found to be significantly up-regulated during 
SMC differentiation from embryonic stem (ES) cells and adventitia stem/progenitor 
cells. Enforced expression of miR-22 by its mimic, while knock-down of miR-22 by 
its antagomiR, promotes or inhibits SMC differentiation from ES cells and adventitia 
stem/progenitor cells, respectively. Expectedly, miR-22 overexpression in stem cells 
promoted SMC differentiation in vivo. MECP2 was predicted as one of the top targets 
of miR-22. Interestingly, the gene expression levels of MECP2 were significantly 
decreased during SMC differentiation, and MECP2 was dramatically decreased in 
miR-22 overexpressing cells, but significantly increased when miR-22 was 
knockdown in the differentiating stem cells. Importantly, luciferase assay showed 
miR-22 substantially inhibited wild type, but not mutant MECP2-3’-UTR-luciferase 
activity. In addition, modulation of MECP2 expression levels affects multiple SMC-
specific gene expression in differentiated ES cells. Mechanistically, our data showed 
that MECP2 could transcriptionally repress SMC gene expression through modulating 
various SMC transcription factors as well as several proven SMC differentiation 
regulators. Evidence also revealed that enrichment of H3K9 tri-methylation around 
the promoter regions of the SMC differentiation regulators genes were significantly 
increased by MECP2 overexpression. Finally, miR-22 was up-regulated by PDGF-BB 
and TGF-β through a transcriptional mechanism during SMC differentiation. 
Conclusion: miR-22 plays an important role in SMC differentiation, and epigenetic 
regulation through MECP2 is required for miR-22 mediated SMC differentiation. 
 
Nonstandard Abbreviations and Acronyms: 
ES, embryonic stem; SMC, smooth muscle cell; miRs, microRNAs; miR-22, 
microRNA-22; miR-34a; microRNA-34a; SmαA, smooth muscle alpha actin; SM-
MHC, smooth muscle-myosin heave chain; SM22α, smooth muscle 22 alpha; SRF, 
serum response factor; pSRF, phosphorylated SRF; Myocd, myocardin; MECP2, 
methyl CpG binding protein 2; H3K9me3, histone H3 trimethyl Lys9; Nox4, NADPH 
oxidase 4; Pla2g7, phospholipase A2, group VII; HDAC7, histone deacetylase 7; Ros, 
reactive oxygen species; PDGF-BB, platelet-derived growth factor; TGF-β, 
transforming growth factor beta; MEF2c, myocyte-specific enhancer factor 2C; SirT1, 
NAD-dependent deacetylase sirtuin-1; AdSca-1
+
 cells, adventitia stem cell antigen 1-
positive cells; CHIP, chromatin immunoprecipitation; RT-qPCR, real time 
quantitative PCR. 
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Introduction 
Smooth muscle cells (SMCs) that form the walls of blood vessels not only provide the 
healthy vessel with its structure and ability to contract under normal conditions, they 
also play a major role in the formation and progression of atherosclerotic plaques. It 
has been widely accepted that SMC differentiation is a critical process during 
cardiovascular development, and SMC proliferative related cardiovascular disease, 
such as atherosclerosis. Therefore, to better understand how vascular SMC 
differentiation being regulated is essential for improving the treatment or prevention 
of cardiovascular disorders and realizing the therapeutic potential of stem cells in 
cardiovascular regenerative medicine. Although recent findings reported from our 
group and others
1-7
 have significantly improved our understanding regarding SMC 
differentiation and cardiovascular system development, the detailed molecular 
mechanisms of SMC differentiation from pluripotent stem cells have not been fully 
clarified.  
microRNAs (miRs) are endogenous, highly conserved, short non-coding 22 
nucleotide RNAs and constitute a novel class of gene expression regulators which 
play important roles in various aspects of development, homeostasis, and disease. 
Interestingly, many miRs are reported to be expressed in a tissue-specific manner, 
suggesting that certain miRs might be important for cell/tissue specification
8
. In 
addition, studies using dicer or drosha deficient embryonic stem (ES) cells have 
suggested that miRs play a role in ES cells self-renewal and differentiation
9-11
. An 
essential role of miRs in cardiovascular development has been demonstrated in a 
study of Dicer-deficient mice which showed that the loss of miRs resulted in severe 
impairment of heart and blood vessel development
12
. Furthermore, it has been shown 
that conditional deletion of Dicer in vascular smooth muscle caused late embryonic 
lethality at embryonic day 16 to 17 due to decreased SMC proliferation and 
differentiation which resulted in thinner vessel walls, impaired contractility, and 
hemorrhage
13, 14
, highlighting the importance of miRs in SMC proliferation and 
differentiation. Although the disruption of miR processing during embryonic 
development provides important insights into the understanding of the functional 
involvements of miRs in cardiovascular development, manipulation of individual 
miRs may offer more precise answers to the significance and exact role of individual 
miRs in SMC differentiation because the elimination of virtually all miRs makes it 
impossible to identify relevant regulatory circuits and related miR targets. microRNA-
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22 (miR-22), has been originally suggested as tumour suppressor
15-17
, was found to 
play an important role in cardiovascular disease. It has been recently reported that 
miR-22 could contribute to cardiac aging by inducing cellular senescence and 
promoting migratory activity of cardiac fibroblasts trough targeting mimecan 
(osteoglycin)
18
. Moreover, miR-22 is up-regulated during human embryonic stem (ES) 
cell differentiation, implying that miR-22 could play a potential role in stem cell 
differentiation
19
. In the present study, we have demonstrated for the first time that 
miR-22 plays an important role in SMC differentiation from stem cells in vitro and in 
vivo by targeting methyl CpG binding protein 2 (MECP2), a well-known epigenetic 
regulator. Furthermore, we have also provided compelling evidence to support that 
MECP2 is a potential transcriptional repressor for SMC-specific gene expression 
during SMC differentiation through an epigenetic modification mechanism. 
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Materials and Methods 
Materials and Methods are available in the online-only Data Supplement. 
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Results 
miR-22 mediates SMC differentiation from ES cells in vitro  
To induce SMC differentiation, ES cells (ES-D3) were re-seeded into collagen-coated 
flasks and cultured in SMC differentiation medium for 2 to 8 days as described in our 
previous studies
1-5, 20-23
.  Consistently, SMC specific markers including smooth 
muscle alpha actin (SMαA) and myosin heave chain (SM-MHC for protein or SM-
myh11 for gene) were significantly increased upon cell differentiation (Figure I). Our 
recent study has suggested that miR-34a plays a functional role in SMC 
differentiation
24
. Interestingly, along with miR-34a another miRNA, miR-22, was 
emerged as one of the top up-regulated miRNAs during SMC differentiation in our 
miRNA microarrays analyses
24
, which was further confirmed by RT-qPCR analysis 
(Figure 1A), suggesting a role for miR-22 in SMC differentiation. To investigate 
whether miR-22 induction was important for SMC differentiation, lose-of-function 
experiments by using Anti-miR™ miR-22 inhibitor (Ambion) were performed in 
differentiating ES cells. Data showed that both gene and protein levels (Figure 1B 
and Figure IIA) of smooth muscle differentiation specific markers (SMA, SM22, 
h1-calponin and SM-myh11) were significantly inhibited by miR-22 knockdown. On 
the other hand, data from the gain-of-function experiments using Pre-miR™ mmu-
miR-22 miRNA Precursor (Ambion) clearly revealed that miR-22 overexpression 
could enhance the gene and protein expression of SMC-specific markers (Figure 1C 
and Figure IIB), suggesting a critical role of miR-22 in SMC differentiation from 
stem cells. Importantly, we also observed that two of important SMC transcription 
factors, serum response factor (SRF) and myocardin (Myocd), were regulated by 
miR-22 in a similar manner to SMC specific genes, while modulation of miR-22 
expression levels in differentiating ES cells has no effect on the expression level of 
another transcriptional factor myocyte enhancer factor 2C (MEF2c) (Figure III), 
suggesting that miR-22 works in concert with SRF and Myocd during SMC 
differentiation from stem cells. 
Functional role of miR-22 in SMC differentiation in vivo 
miR-22 over-expressing (pLL3.7-GFP-miR-22) and control (pLL3.7-GFP) ES cells 
were generated to facilitate our in vivo SMC differentiation study. GFP-positive cells 
with high purity (Figure IVA) were sorted out from ES cells infected with pLL3.7-
GFP- or pLL3.7-GFP-miR-22 lentivirus and maintained in ES cell culture medium. 
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No significant differences were observed between the sorted cells and their parent ES 
cells in terms of morphology, self-renew and pluripotency when they were cultured in 
ES cell culture medium for up to at least five passages (data not shown). The 
expression level of miR-22 was low and similar among parental ES cells, control and 
miR-22 over-expressing ES cells (Figure IVB), indicating the expressional 
machinery of miR-22 was inhibited under stem cell culture condition. Similar to their 
parent cells, miR-22 expression was significantly up-regulated during differentiation, 
and compared to control ES cells (pLL3.7-GFP), the expression levels of miR-22 in 
miR-22 overexpressing ES cells (pLL3.7-GFP-miR-22) were further up-regulated at 
day 8 of differentiation (Figure IVB), suggesting that the inhibitory mechanism of 
miR-22 under stem cell culture condition has been removed and miR-22 was 
successful up-regulated in these cells during SMC differentiation. Consequently, 
more SMCs were differentiated from miR-22 over-expressing ES cells (Figure IVC), 
further confirming that miR-22 promotes SMC differentiation. To further explore the 
functional relevance of miR-22 in SMC differentiation in vivo, pLL3.7-GFP and 
pLL3.7-GFP-miR-22 ES cells were subcutaneously injected into C57BL/6J mice with 
100ng/ml of PDGF-BB to promote in vivo SMC differentiation as described in our 
previous studies
1, 2
. We observed a higher percentage of cells were SM-MHC-positive 
SMCs in the implants of miR-22 overexpressing ES cells than that of control cells as 
demonstrated by immunofluorescence staining with antibody against GFP and SM-
MHC (Figure VA and VB). As expected, the majority of cells in the Matrigel 
implants were GFP-positive, implying its exogenous origins (Figure VA). 
Furthermore, our data showed that the expression levels of miR-22, SMαA and SM-
MHC in the Matrigel implants of pLL3.7-GFP-miR-22 ES cells were significantly 
higher than that of control cells (Figure VC), further confirming the efficiency of 
miR-22 over-expression and the importance of miR-22 in SMC differentiation in vivo. 
Taken together, these data firmly suggest a regulatory role of miR-22 in SMC 
differentiation from stem cells in vitro and in vivo. 
Functional importance of miR-22 in adventitia stem/progenitor cell differentiation 
towards SMCs   
Cells positive for Sca-1 has been reported as one of the major blood vessel residential 
stem/progenitor cells which contribute to atherosclerosis of vein-graft
25
. To further 
explore its relevance or implication of miR-22 in vascular diseases, adventitia stem 
cell antigen 1-positive (AdSca-1+) cells isolated from vessel adventitia as described 
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previously
2, 25
, were induced to differentiate into SMCs. RT-qPCR analyses showed 
that miR-22 was significantly up-regulated during SMC differentiation from AdSca-
1
+
 cells, along with various SMC differentiation genes (Figure VIA). Importantly, 
data from miR-22 over-expression and knockdown experiments (Figure VIB and 
VIC) revealed that enforced expression of miR-22 by its precursor significantly 
increased all the SMC genes examined, while knock-down of miR-22 by its 
antagomiR/inhibitor dramatically inhibited these gene expression, respectively, 
suggesting a functional involvement of miR-22 in SMC specifications of the vascular 
residential stem/progenitor cells. 
Target gene, MECP2, is negatively regulated by miR-22 through the binding sites 
within 3’UTR   
By utilising similar strategies as described in previous study
26
, MECP2 was predicted 
as one of the top targets of miR-22. Firstly, bioinformatics search for putative miR-22 
binding sites within the MECP2 mRNA by using several online free accessible 
computational algorithmic databases (e.g. TargetScan 4.0 and PicTar) revealed that 
the seed sequence of miR-22 is predicted to hybridize to serval regions of MECP2 
3’UTR, which is evolutionarily conserved among vertebrate species. Secondly, at 
least four highly conserved binding sites for miR-22 have been identified within 
MECP2 3’UTR (Figure VIIA and VIIB). Finally, by using mFold software 
(http://mfold.rna.albany.edu/?q=DINAMelt/Two-state-melting) we also found a 
favourable minimum loop-free energy (-10.70 to -12.0 kcal/mol) in the formation of 
the miR-22:MECP2 3’UTR duplex stem-loop for all four miR-22 binding sites, 
suggesting that miR-22 is involved in translational repression of MECP2. As expected, 
MECP2 gene expressions were significantly down-regulated (Figure 2A), and 
displayed a negative correlation with the gene expression levels of miR-22 during 
SMC differentiation (Figure 1A), suggesting that miR-22 may negatively regulate 
MECP2. Such notion has been firmly supported by the findings that MECP2 gene 
levels were significantly down-regulated or up-regulated by over-expression or 
inhibition of miR-22 in the differentiating ES (Figure 2B) or AdSca-1
+
 cells (Figure 
VIB and VIC), respectively. Furthermore, as shown in Figure VC MECP2 gene 
expression levels in the Matrigel implants of pLL3.7-GFP-miR-22 ES cells were 
significantly lower than that of control cells, indicating that MECP2 was also 
negatively regulated by miR-22 during in vivo SMC differentiation. Expectedly, the 
protein levels of MECP2 were dramatically inhibited by miR-22 over-expression 
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(Figure 2C and IIC), indicating that MECP2 is negatively regulated by miR-22 
directly or indirectly. To distinguish these two possibilities, we first attempted to 
generate the miRNA reporter containing full length of MECP2 3’UTR (~8500bps), 
but unsuccessful. Instead, three MECP2 3’UTR reporters containing the segments 
spinning through the first two miR-22 binging sites (1567-2698), the third binding site 
(4142-4968) and the fourth binding site (8173-9137) were successfully generated in 
this study, designated as pmiR-Luc-MECP2-A, -B and –C (Figure VIIA and VIIB), 
respectively. Data from our miRNA reporter assay showed that the activity of 
luciferase of reporter A and C, but not reporter B, was significantly down-regulated 
by miR-22 over-expression (Figure 2D). Most importantly, the site-directed 
mutagenesis of the predicted miR-22 binding site(s) in the MECP2 3’UTR reporter(s) 
experiments showed that the 2
nd
 (within reporter A) and 4
th
 (within reporter C) 
binding sites are required for MECP2 3’UTR reporter activity inhibition mediated by 
miR-22 (Figure 2E).  
MECP2 over-expression abolished miR-22 mediated SMC gene expressions 
We have provided solid evidence to support that MECP2 is an authentic miR-22 
target during SMC differentiation. To investigate the potential role of MECP2 in 
SMC differentiation, MECP2 knockdown in the differentiating ES cells was 
conducted by using specific MECP2 siRNA. Data showed that MECP2 knockdown 
significantly up-regulated SMC specific marker expressions (Figure 3A), suggesting 
that MECP2 inhibition can recapitulate the effects of miR-22 during SMC 
differentiation from ES cells. Conversely, MECP2 over-expression significantly 
repressed SMC specific marker expressions (Figure 3B and IID), suggesting that 
MECP2 acts as a repressor of SMC differentiation genes during SMC differentiation. 
To further explore the functional importance of MECP2 in miR-22-mediated SMC 
differentiation, control or MECP2 over-expression vector were transfected into day 
2~3 differentiating control (pLL3.7-GFP) or miR-22 over-expressing (pLL3.7-GFP-
miR-22) ES cells, respectively. RT-qPCR analyses showed that while miR-22 (2
nd
 
columns) or MECP2 (3
rd
 columns) over-expression alone in the differentiating ES 
cells were significantly up-regulated or down-regulated the gene expression levels of 
various SMC differentiation markers (Figure 3C) and specific transcription factors 
(Figure VIII), respectively, re-activation of MECP2 almost completely abolished 
these gene up-regulations induced by miR-22 over-expression (4
th
 columns), 
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suggesting that MECP2 repression is required for miR-22 mediates SMC gene 
expression during SMC differentiation from ES cells. 
Functional importance of SRF binding site within SMC-specific genes in MECP2-
mediated SMC gene expression 
We have demonstrated clearly that SMC specific gene expression was repressed by 
MECP2 gene activation. To further explore the underlying molecule mechanism by 
which MECP2 regulates SMC gene expression, luciferase activity assays were 
conducted in differentiating ES cells using respective SMC gene promoter reporters, 
pGL3-Luc-SMαA and pGL3-Luc-SM22α. Data showed that the overexpression of 
MECP2 in differentiating ES cells significantly inhibited SMαA and SM22α gene 
promoter activities (Figure IXA), indicating that MECP2 over-expression can repress 
specific SMC gene expression at transcriptional level. Since the functional 
importance of SRF binding element (CArG) within promoter region of SMC-specific 
genes has been well-documented in SMC gene regulation
27
, we thus wondered if such 
elements also play a role in MECP2-mediated SMC gene repression. For such 
purpose, another set of luciferase assays using SRF binding site mutants (pGL3-Luc-
SMαA-SRFmu and pGL3-Luc-SM22α-SRFmu) generated in our previous study1 were 
carried out in differentiating ES cells. We observed that mutating the SRF binding 
element within SMC gene promoters almost completely nullified the inhibitory 
effects of MECP2 over-expression on SMC gene transcriptional activity (Figure 
IXA), suggesting that SRF binding site(s) within the promoters is required for 
MECP2-mediated SMC gene repression. However, we observed no significant 
enrichment of MECP2 within the promoter regions of SMC genes as demonstrated by 
ChIP assays using MECP2 specific antibody (Figure IXB) suggesting no direct 
binding of MECP2 to SMC gene promoters. Furthermore, as expected although we 
observed a huge degree of SRF enrichment on SMC gene promoter (up to 10 folds 
enrichment) in separate CHIP assays using SRF specific antibody, such enrichment 
was not affected by MECP2 over-expression (Figure IXC), suggesting that MECP2 
plays no significant role in modulation of SRF binding to SMC-specific gene 
promoters.  
SMC transcription factors SRF and Myocd are transcriptionally repressed by 
MECP2 
Our previous data showed that the gene expression levels of SRF and Myocd, but not 
the MEF2c, were significantly regulated by miR-22 (Figure III). Importantly, data 
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shown in Figure 4A revealed that these two transcription factors were regulated by 
MECP2 in an opposite manner to miR-22, implying an important role of MECP2 in 
regulation of these two transcription factors during SMC differentiation. Such 
possibility has been clearly supported by the data obtained from luciferase activity 
assays using respective SRF, MEF2c and Myocd gene reporter plasmids (pGL3-Luc-
SRF, pGL3-Luc-MEF2c and pGL3-Luc-Myocd) generated in our previous study
1
 
(Figure 4B). Interestingly, CHIP assays with MECP2 antibody showed a significant 
enrichment of MECP2 within the promoter regions of SRF (up to 3 folds) and Myocd 
(up to 20 folds), and such enrichments were further enhanced by MECP2 over-
expression (Figure 4C), suggesting that MECP2 directly binds to SRF and Myocd 
gene promoters. Taken together, our data clearly demonstrated that MECP2 
transcriptionally repress SMC transcription factor gene expression during SMC 
differentiation from stem cells through its direct binding to their promoter regions. 
Other SMC differentiation regulators are regulated by miR-22 and MECP2 
Since transcription factor nuclear factor erythroid 2-related factor 3 (Nrf3)
5
, NADPH 
oxidase 4 (Nox4)
21
, platelet-activating factor acetylhydrolases (Pla2g7)
2
, histone 
deacetylases 7 (HDAC7)
20
 and DNA/RNA binding proteins [heterochromatin Protein 
1γ (Cbx3)3, heterogeneous nuclear ribonucleoprotein (hnRNP) A2B14 and A11] have 
been previously identified as important SMC differentiation regulators in our SMC 
differentiation system, therefore, we wondered whether miR-22 and/or MECP2 plays 
any role in regulation of these genes. To this aim, the gene expression levels of above 
SMC differentiation regulators were examined in the cells over-expressing miR-22 or 
MECP2. We found the gene expression levels of Nox4, HDAC7 and Pla2g7 were 
consistently regulated by miR-22 (Figure 5A) and MECP2 (Figure 5B) in an 
opposite way. Importantly, these three genes were co-regulated by miR-22 and 
MECP2 in a similar manner to other SMC differentiation genes (Figure VIII), 
suggesting miR-22 and/or MECP2 mediated SMC differentiation at least partially 
through regulation of these three reported SMC differentiation modulators. 
Furthermore, data from luciferase assays using a functional Pla2g7 gene promoter 
reporter (pGL3-Luc-Pla2g7-P2, harbouring 387bps of Pla2g7 gene promoter 
fragment located between ~2.4 to 2.0 kb upstream of the translation start site of 
Pla2g7 gene) and a control reporter (pGL3-Luc-Pla2g7-P10, located within exon 1 of 
Pla2g7 gene) generated in our previous study
2
 showed that the promoter activity of 
pGL3-Luc-Pla2g7-P2, but not pGL3-Luc-Pla2g7-P10, was significantly regulated by 
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MECP2 over-expression (Figure 5C). Finally, up to 4 times of MECP2 enrichment 
within Pla2g7 gene promoter (region 2) was observed, and MECP2 over-expression 
further increased the accumulation of MECP2 within Pla2g7 gene promoter, while no 
apparent enrichment of MECP2 within the adjacent promoter area (region 10) was 
observed in the MECP2-CHIP assays (Figure 5D), suggesting that MECP2 regulates 
Pla2g7 gene expression through direct interacting with the region 2 (-2.4 to -2.0 kb) 
of Pla2g7 gene promoter. Similarly, both Nox4 and HDAC7 were regulated by 
MECP2 through a transcriptional mechanism as demonstrated in promoter activity 
analyses (Figure XA) and MECP2-CHIP assays (Figure XB), respectively. 
MECP2 represses SMC gene expression through increasing H3K9 methylation 
within the gene promoters of SRF, Myocd and Pla2g7 
It has been well-documented that MECP2 is capable of binding specifically to 
methylated DNA and involves in gene silencing, and methylation of lysine H3K9 is 
closely associated with gene transcriptional repression
28
. To further elucidate the 
molecular mechanism by which MECP2 represses SMC gene expression, we first 
examined if H3K9me3 expression levels were regulated by MECP2. Data from over-
expression experiments showed that H3K9me3 protein expression levels were not 
significantly affected by MECP2 over-expression (Figure 6A). However, our CHIP 
assays with H3K9me3 specific antibody showed a variety of degree of H3K9me3 
enrichment within the promoter regions of examined genes (up to 2.5 folds for 
SMαA/SM22α; 23 folds for SRF, 40 times for Myocd and 96 times for Pla2g7, 
respectively), and importantly such enrichments were further enhanced by MECP2 
over-expression for SRF, Myocd and Pla2g7 gene promoters (Figure 6C and 6D), 
but not for SMαA/SM22α (Figure 6B), which are consistent with the enrichment of 
MECP2 within respective gene promoters as observed in our above CHIP assays with  
MECP2 antibody (Figures IXB, 4C, and 5D). Expectedly, miR-22 over-expression 
significantly inhibited H3K9me3 enrichment within the promoter regions of SRF, 
Myocd and Pla2g7, but no such inhibition was observed within the promoter regions 
of SMαA/SM22α (Figure XI). Taken together, above data clearly demonstrated that 
MECP2 represses SMC-specific gene expression, at least partially through increasing 
H3K9 tri-methylation within the gene promoters of SMC specific transcription 
factors (SRF and Myocd) and differentiation modulators (eg. Pla2g7).  
PDGF-BB and TGF-β up-regulate miR-22 through a transcriptional mechanism 
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Our previous studies have suggested that during stem cell differentiation, auto-
secreted growth factors (e.g. PDGF-BB
20, 23
 and TGF-β21) from the differentiating 
cells activate their respective down-dream signal pathways, which in turn trigger 
SMC differentiation program. We wondered if miR-22 was one of such signal 
molecules during SMC differentiation. Indeed, RT-qPCR analyses showed that both 
PDGF-BB and TGF-β were significantly up-regulated miR-22 expression in a dose-
dependent pattern (Figure XIIA and XIIB). Moreover, PDGF-BB and TGF-β 
treatments also increased the expression levels of miR-22 precursor and primary 
RNAs (Figure XIIC and XIID), suggesting that miR-22 was regulated by PDGF-BB 
and TGF-β at transcriptional level. Such a notion was further confirmed by incubating 
the cells with RNA synthesis inhibitor, actinomycin D (1µg/ml for 6 hours), in which 
the data showed that Actinomycin D incubation ablated the effect of PDGF-BB and 
TGF-β treatments on the expression levels of miR-22 (Figure XIIE and XIIF).    
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Discussion 
Accumulating evidence in the literature has revealed that the gene regulatory program 
of SMC differentiation from pluripotent stem cells is orchestrated by a coordinated 
molecular network composing of various signaling pathways and molecules, such as 
Myocd–SRF complex, extracellular matrix, integrins, retinoid receptor, TGF family, 
notch family, reactive oxygen species, microRNAs, HDACs, and others (eg, paired-
like homeodomain 2 and protein inhibitor of activated STAT-1)
29, 30
. Despite 
enormous efforts have been put into this field in the past decades, our understandings 
into the molecular mechanisms underlying SMC differentiation are still far from 
complete. In the present study, we have further advanced our knowledge in this topic 
by uncovering an important role for miR-22 in regulating SMC specific gene 
expression and SMC differentiation from murine ES cells in vitro and in vivo. 
Furthermore, we present the first evidence of a functional role for MECP2 in SMC 
differentiation and SMC-specific gene regulation. Importantly, we have provided 
compelling evidence to support that the identified target gene, MECP2, functions as 
an important SMC differentiation gene repressor during SMC differentiation from 
stem cells. 
It has been reported that the human miR-22 gene, located in a minimal loss of 
heterozygosity region between markers D17S1866 and D17S1574 on chromosome 17 
(17p13.3) (close to TP53) in cancer cells, overlaps the exon 2 region of the spliced 
non-coding C17orf91 transcript
31
, and the primary miR-22 is processed from a capped, 
polyadenylated transcript
32
, while the mouse counterpart is also mapped to a cancer 
associated genomic region
33
, implying an important role for miR-22 in cancers. 
Indeed, several studies have independently identified miR-22 as a tumour 
suppressor
15-17
. Moreover, it has been recently reported that miR-22 could contribute 
to cardiac aging by inducing cellular senescence and promoting migratory activity of 
cardiac fibroblasts through targeting osteoglycin
18
, suggesting that miR-22 might play 
a role in cardiovascular disease. Furthermore, it has been documented that miR-22 is 
up-regulated during human ES cell differentiation
19
, induced by TPA during 
monocytic differentiation from HL-60 leukemia cell lines
34
, and is close associated 
with erythroid maturation
35
, implying that miR-22 could play a potential role in 
hematopoietic cell differentiation and maturation. However, the functional role of 
miR-22 in SMC differentiation from pluripotent stem cells remains to be explored.  In 
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the present study, miR-22 has been signalled out from our microRNA screening 
experiments as one of the top potential miRNA candidates with high expression levels 
during SMC differentiation from ES cells. Importantly, by utilizing miRNA gain/lose-
of function analyses, we confirmed a critical role for miR-22 in SMC differentiation 
from ES cells in vitro. Furthermore, by generating miR-22 over-expressing ES cell 
lines and using our well-established in vivo SMC differentiation model (Martigel-stem 
cells-PDGF-BB complex implantation)
1, 2
 we provide first evidence to support that 
miR-22 plays an important role in embryonic SMC differentiation in vivo. These data 
firmly demonstrated for the first time that miR-22 is an important SMC differentiation 
regulator. 
Identifying and validating the genuine mRNA target(s) that are responsible for or 
mediate any given functions of examined miRNA(s) is fundamental and most difficult 
step in miRNA study. Since we have demonstrated clearly that miR-22 can regulate 
SMC differentiation in vitro and in vivo, we sought to identify the downstream mRNA 
target(s) which is responsible for miR-22 mediated SMC differentiation from stem 
cells. For this purpose, we utilised several computational algorithmic databases 
including Targetscan (www.targetscan.org), pictar (www.pictar.mdc-berlin.de), and 
miRanda (www.microrna.org) to predict the putative mRNA targets of miR-22, and 
found that MECP2 was emerged as a top targets of miR-22. Interestingly, the MECP2 
mRNA has a long 3’ UTR of about 8.7 kb which bears evolutionarily conserved 
miRNA target sites, suggesting that it might be regulated by miRNAs. Importantly, 
we have identified four highly conserved binding sites for miR-22 within MECP2 
3’UTR as shown in Figure VIIA and VIIB, implying that MECP2 is an mRNA 
target of miR-22. Indeed, such notion that MECP2 is a bona-fide miR-22 target 
during SMC differentiation has been supported by several lines of evidence: Firstly, 
MECP2 gene expression was significantly down-regulated during SMC 
differentiation from stem cells (Figure 2A) which displayed a perfect and negatively 
association with miR-22 expression levels (Figure 1A). Secondly, MECP2 gene and 
protein expression levels were adversely regulated by miR-22 as demonstrated in 
miR-22 over-expression and inhibition experiments (Figure 2B and 2C). Thirdly, 
miR-22 over-expression dramatically down-regulates MECP2 3’UTR activity, but 
such down-regulation was completely abolished when two of the miR-22 binging 
sites within MECP2 3’UTR were mutated (Figure 2D and 2E). Interestingly, the 
Accepted Paper, Published in Arterioscler Thromb Vasc Biol. 2015 
Oct;35(10):2134-44. doi: 10.1161/ATVBAHA.115.305420. 
 16 
binding sites that have been proven to be responsible for miR-22 mediated MECP2 
gene regulation in this study are the ones located around ~2797bp and ~8347bps, but 
not the one located in the middle of 3’UTR (~4537bp), which is consistent with one 
of the principal rules of microRNA–mRNA interactions that for gene with long 3' 
UTRs, the position of miRNA binding site(s) that is not too far away from the poly(A) 
tail or the termination codon can significantly improve site efficacy
36
, therefore 
represents a higher possibility of these binding sites being more functional relevance. 
However, it is noteworthy to mentioned that since we failed to obtain such a mutant 
with only 1
st
 miR-22 binding site (~1577bp) being mutated in this study, we could not 
exclude the importance of this binding site in mediating MECP2 3’UTR activity by 
miR-22. Nonetheless, our data clearly demonstrated that MECP2 is a genuine mRNA 
target of miR-22. Finally but importantly, comparing with the Matrigel plugs 
implanted with control ES cells the MECP2 gene expression levels in the Matrigel 
implants with miR-22 over-expressing ES cells were much lower (Figure VC), 
suggesting that MECP2 gene expression is negatively regulated by miR-22 and 
MECP2 is also a true mRNA target of miR-22 during in vivo SMC differentiation 
from stem cells. 
Apart from MECP2 that has been identified and validated as a bona-fide miR-22 
mRNA target during SMC differentiation in the current study, several other miR-22 
mRNA targets including oncogene EVI-1
37
, HDAC4
38
, PTEN
39
, estrogen receptor α 
(ER α)40, c-Myc binding protein (MYCBP)33,  MYC associated factor X (Max)34, 
TET2
41
, have been reported in cancer cells. However, none of them was proved to be 
a true miR-22 mRNA target in our SMC differentiation system. Among them, only 
the expression levels of EVI-1 was negatively associated with miR-22 expression 
levels in the miR-22 over-expression and/or inhibition experiments, but over-
expression of miR-22 failed to down-regulate ZVI-1 3’UTR luciferase activity (data 
not shown). These data suggested such a possibility that some of miR-22 mRNA 
targets are cell-specific or miR-22 likely plays a divergent role under various 
physiological and pathological conditions through targeting distinct target gene(s).  
One of novel mechanistic findings in the present study is that we provided first time 
but compelling evidence to support that MECP2 repression is required for miR-22 
mediated SMC differentiation from stem cells, and MECP2 functions as an inhibitory 
regulator in SMC differentiation gene expression. MECP2 is the funder member of 
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methyl-CpG binding domain proteins that can specifically bind to both methylated 
and unmethylated DNA and recruit distinct interacting protein partners to establish a 
repressive or active chromatin environment
42
, respectively, and has been reported to 
be involved in a variety of biological functions and diseases, such as rett syndrome 
and neural development
43, 44
, modulating human iNOS gene expression
45
, regulation 
of myofibroblast differentiation during pulmonary fibrosis
46
, myogenesis
47
, neural 
differentiation from ES cells
48
 or neural precursors
49
, adult neurogenesis
50
, neuron 
electrophysiological properties
51
 and embryonic development
52
. Importantly, recent 
study has suggested that MECP2 can switch their transcriptional activity in the 
epigenetic regulation of neural chromatin and gene expression through binding 
hydroxymethylcytosine (5hmC) or 5-methylcytosine (5mC) containing DNA with a 
similar affinity. It has been reported that MeCP2 binding to 5hmC can facilitate 
transcription in neural cell types while at the same time acting in repression when 
bound to 5mC containing DNA
53
. In the present study, we have provided compelling 
evidence to support that MECP2 is an important SMC differentiation mediator by 
transcriptional regulation of the gene expression of SMC specific markers, 
transcriptional factors and other SMC differentiation regulators. So far, several 
molecular roles have been described for MeCP2 in gene regulation: transcriptional 
repression, activation of transcription, nuclear organization, and splicing
42
. In 
consistent its roles in gene regulation, we have provided strong evidence in the 
current study which firmly demonstrated that MECP2 is a transcription repressor to 
regulate SMC-specific gene expression (SMαA, SM22α, SRF, Myocd, Nox4, 
HDAC7 and Pla2g7) during SMC differentiation (Figure 4 and 5, Figure IX and X). 
We obtained no evidence to show that MECP2 represses SMC-specific gene 
expression through direct binding to their gene promoters. Instead, we found that 
MECP2 could bind directly to the gene promotes of SMC transcription factors (SRF 
and Myocd) and proven SMC differentiation modulators (e.g. Pla2g7, Nox4 and 
HDAC7) (Figure 4C and 5D, Figure IX and X).  
Another important finding of the present study is that we further demonstrate that 
MECP2 acts as a potential transcriptional repressor for SMC gene regulation through 
modulating epigenetic modifications of SMC-specific transcription factors and/or 
SMC differentiation modulators. DNA methylation and histone modifications 
represent the major epigenetic mechanisms implicated in the regulation of gene 
transcription in mammals. It has been widely accepted that hypomethylation of the 
Accepted Paper, Published in Arterioscler Thromb Vasc Biol. 2015 
Oct;35(10):2134-44. doi: 10.1161/ATVBAHA.115.305420. 
 18 
DNA surrounding the proximal promoter region is a prerequisite for gene activation, 
whereas heavy methylation leads to gene silencing. Previous studies reported that 
MeCP2 was associated with histone methyltransferase activity in vivo and such 
activity is directed against Lys9 of histone H3
54
. Moreover, our previous data also 
showed that H3K9 methylation was enriched within SMC specific gene promoter 
regions in the differentiating stem cells
3
. These data prompted us to investigate if 
MECP2 represses SMC-specific gene expression during stem cell differentiation is 
through modulating DNA methylation. In the current study we have provided for the 
first time evidence to support a notion that instead of increasing H3K9me3 protein 
production in the differentiating stem cells, MECP2 increases H3K9 tri-methylation 
within the gene promoters of SMC-specific transcription factors and other SMC 
differentiation regulators, resulting in SMC gene repression during stem cell 
differentiation towards SMC lineage. However, the functional involvements of 
MECP2 in the regulation of other epigenetic modifications remain to be fully 
elucidated.  
Finally, we have demonstrated that miR-22 is up-regulated by PDGF-BB and TGF-β 
through a transcriptional mechanism during SMC differentiation. Interestingly, apart 
from miR-22, our unpublished data suggests that PDGF-BB and/or TGF-β also 
transcriptionally up-regulates another reported SMC differentiation miRNA, miR-
34a
24
. Taken together, we have successful identified a novel function of miR-22 in 
SMC differentiation from stem cells in vitro and in vivo, and provided comprehensive 
evidence to support that MECP2 is a genuine mRNA target of miR-22 during SMC 
differentiation, and repression of MECP2 in the differentiating stem cells is required 
for miR-22 mediated SMC differentiation. Moreover, we have revealed that MECP2 
regulates SMC gene expression through a transcriptional mechanism as well as an 
epigenetic signal pathway. Furthermore, we have found that miR-22 and/or MECP2 
modulates SMC-specific gene expression through regulating other proven SMC 
differentiation masters, and have exemplify demonstrated that MECP2 
transcriptionally regulates other SMC differentiation modulators gene expression 
through its direct binding to their promoter region and increasing H3K9 tri-
methylation within the gene promoters. Therefore, based on the findings presented in 
the current study and our previous study
24
 we propose the following molecular 
mechanism through which miRNAs mediate SMC differentiation (Figure XIII): 
during stem cell differentiation, miR-22 and miR-34a were transcriptionally up-
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regulated by PDGF-BB and/or TGF-β auto-secreted from differentiating cells. On the 
one hand, the inhibitory effects of MECP2 on SMC specific transcription factors 
(SRF and Myocd) as well as other SMC differentiation master regulators (e.g. Pla2g7, 
Nox4 and HDAC7) were removed/de-repressed by up-regulated miR-22, triggering 
SMC-specific gene expression programme and promoting SMC differentiation. On 
the other hand, increased miR-34a up-regulated its target gene, SirT1, through an 
unusual manner, which in turn transcriptionally regulated three SMC transcriptional 
factors (SRF, Myocd and MEF2C), resulting in SMC differentiation gene activation 
and SMC differentiation. Undoubtedly, the findings presented in this study will 
significantly increase our knowledge of the molecular mechanisms underlying SMC 
differentiation and benefit future stem cell application in cardiovascular regenerative 
medicine. 
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Significance 
 
Smooth muscle cell (SMC) differentiation is a complicated process involving many 
transcription factors and regulators. Studies focused on molecular mechanisms 
governing SMC differentiation are crucial for improving our understanding of the 
pathophysiological process of cardiovascular development and various cardiovascular 
diseases formation/progression, and developing novel therapeutic strategies for these 
diseases.  In this study, we have uncovered a previously unrecognised functional role 
of miR-22 in stem cell differentiation towards SMCs in vitro and in vivo. We have 
identified MECP2 is a bona-fide miR-22 target during SMC differentiation, which 
functions as an inhibitory regulator in SMC differentiation gene expression. 
Importantly we have further demonstrated that MECP2 acts as a potential 
transcriptional repressor for SMC gene regulation through modulating epigenetic 
modifications of SMC-specific transcription factors and/or SMC differentiation 
modulators. Our data provide novel molecular insights into the regulation of SMC 
differentiation and enhance our knowledge of SMC differentiation and vascular 
development.  
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Figures 
Figure 1. miR-22 regulates SMC differentiation from ES cells.  
(A) Induction of miR-22 during SMC differentiation from ES cells. Day 0 samples 
were undifferentiated ES cells and served as negative control. (B) miR-22 inhibition 
impairs SMC marker expressions. Day 3 differentiating ES cells were transfected with 
miR-22 inhibitor or negative control, and cultured in SMC differentiation medium for 
48 hours. (C) miR-22 overexpression promotes SMC marker expressions. ES cells 
were transfected with miR-22 precursor or negative control, and cultured in SMC 
differentiation medium for 48~72 hours. Total RNA and protein were harvested and 
subjected to RT-qPCR and Western blot analyses, respectively. The data presented 
here are representative or mean±S.E.M. of three independent experiments. *P<0.05. 
  
Accepted Paper, Published in Arterioscler Thromb Vasc Biol. 2015 
Oct;35(10):2134-44. doi: 10.1161/ATVBAHA.115.305420. 
 27 
Figure 2. MECP2 was identified as a target gene of miR-22 during SMC 
differentiation.  
(A) Gene expression levels of MECP2 during SMC differentiation from ES cells. (B 
and C) miR-22 negatively regulates MECP2 expression levels. Total RNA and protein 
were harvested as described in Figure 1 and subjected to RT-qPCR (B) and Western 
blot (C) analyses, respectively. (D-E) Binding sites located around ~2797 and ~8347 
of MECP2 3’UTR are required for miR-22 mediated MECP2 gene repression. miR-22 
precursor or negative control and wild type MECP2 3’UTR reporters (pmiR-Luc-
MECP2-A, B, C) or three indicated mutants [pmiR-Luc-MECP2-A bindings site 2 
(bs2
mu
), combinational mutations (bs1/2
mu
) and pmiR-Luc-MECP2-C bindings site 
(bs
mu
)] were co-transfected into day 2~3 differentiating ES cells and luciferase 
activity assay were measured at 48 hours post-transfection. The data presented here 
are representative or mean± S.E.M. of three to four independent experiments. 
*P<0.05 (treatment versus day 0 or control).  
 
Accepted Paper, Published in Arterioscler Thromb Vasc Biol. 2015 
Oct;35(10):2134-44. doi: 10.1161/ATVBAHA.115.305420. 
 28 
Figure 3. MECP2 repression is required for miR-22 mediated SMC gene 
expressions.  
(A) MECP2 knockdown increases SMC gene expression. Day 2~3 differentiating ES 
cells were transfected with control siRNA (ctrl siRNAs) or MECP2 specific siRNA 
(MECP2 siRNAs), and cultured in SMC differentiation medium for another 48 or 72 
hours. Total RNAs were harvested and subjected to RT-qPCR analyses. (B) MECP2 
over-expression inhibits SMC gene expression. Day 2~3 differentiating ES cells were 
transfected with control (pCMV5) or MECP2 over-expression plasmid (pCMV5-
MECP2), and cultured in SMC differentiation medium for another 48 or 72 hours. 
Total RNAs and proteins were harvested and subjected to RT-qPCR and Western 
Blotting analyses, respectively. The data presented here are representative (insert) or 
mean± S.E.M. of three independent experiments, *P<0.05. (C) MECP2 over-
expression abolished SMC gene expression induced by miR-22. Day 2 differentiating 
control (pLL3.7-GFP) and miR-22 over-expressing (pLL3.7-GFP-miR-22) ES cells 
were transfected with respective control (pCMV5) and MECP2 over-expression 
(pCMV5-MECP2) plasmids, and cultured in SMC differentiation medium for further 
48 to 72 hrs. Total RNAs were harvested and subjected to RT-qPCR analyses. The 
data presented here are mean±S.E.M. of three independent experiments.  
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Figure 4. SMC transcription factor gene expressions were negatively regulated 
by MECP2.  
(A) The expression levels of SRF and Myocd, but not the MEF2c, were significantly 
down-regulated by MECP2 over-expression. Total RNAs were harvested as described 
in Figure 3A. (B) Promoter activities of SRF and Myocd genes were modulated by 
MECP2. Day 2~3 differentiating ES cells were transfected with luciferase reporter 
plasmids pGL3-SRF-Luc, pGL3-MEF2c-Luc or pGL3-Myocd-Luc (0.15μg/2.5×104 
cells) together with pCMV5 or pCMV5-MECP2 (0.2μg/2.5×104 cells). pShuttle-LacZ 
(0.2μg/2.5×104cells) was included as control. Luciferase and β-galactosidase activity 
assays were detected 48 hours after transfection. The data presented here are 
mean±S.E.M. of four independent experiments. *P<0.05 (vs. control). (C) MECP2 
binds directly to the promoter regions of SRF and Myocd genes. ChIP assays were 
performed using antibodies against MECP2 or normal IgG, respectively, as described 
in online supplemental data. PCR amplifications of the adjacent regions were included 
as additional control for specific promoter DNA enrichment. The data presented here 
are mean±S.E.M. of three independent experiments. *P<0.05 (vs. control). 
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Figure 5. Other reported SMC differentiation regulators were negatively 
modulated by MECP2.  
(A) Gene expression levels of other reported SMC differentiation regulators in the 
differentiating cells transfected with control and miR-22 precursor. Total RNAs were 
harvested as described in Figure 1C. (B) Three reported SMC differentiation 
regulators were regulated by MECP2. Total RNAs were harvested as described in 
Figure 3A. (C) Promoter activities of Pla2g7 gene were significantly repressed by 
MECP2 over-expression. Day 2~3 differentiating ES cells were transfected with 
luciferase reporter plasmids pGL3-Pla2g7-2-Luc or pGL3-Pla2g7-10-Luc 
(0.15μg/2.5×104 cells) together with pCMV5 or pCMV5-MECP2 (0.2μg/2.5×104 
cells). The data presented here are mean±S.E.M. of four independent experiments. 
*P<0.05 (vs. control). (D) MECP2 binds directly to the promoter (region 2) of Pla2g7 
gene. ChIP assays were performed as described in Figure 5C. PCR amplifications of 
the adjacent region (region 10) were included as additional control for specific 
promoter DNA enrichment. The data presented here are mean±S.E.M. of three 
independent experiments. *P<0.05 (vs. control). 
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Figure 6. MECP2 modulates H3K9me3 enrichment on the respective gene 
promoter regions of SRF, Myocd and Pla2g7.  
(A) H3K9me3 protein levels were not affected by MECP2 over-expression. Total 
proteins were harvested as described in Figure 3B. (B) The enrichment of H3K9me3 
within the promoter regions of SMαA and SM22α genes were not affected by MECP2 
over-expression. (C) MECP2 over-expression increases H3K9me3 bindings to the 
promoter regions of SRF and Myocd genes. (D) The enrichment of H3K9me3 within 
the promoter regions of Pla2g7 gene was significantly increased by over-expression 
of MECP2. ChIP assays were performed using antibody against H3K9me3 or normal 
mouse IgG, respectively, as described above.  The data presented here are 
mean±S.E.M. of three independent experiments. *P<0.05 (vs. control). 
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Methods & Materials 
Materials. Antibodies against MECP2 (goat, N-17, sc-5755) and SRF (rabbit, G-20, 
sc-335) were purchased from Santa Cruz Biotech, USA. Antibody against Smooth 
Muscle Myosin Heavy Chain (SM-MHC) was from AbD Serotec (Rabbit, AHP1117). 
Antibodies against MECP2 (rabbit, ab2828, CHIP grade), SM22α (rabbit, Ab14106) 
and calponin (rabbit, Ab46794) were from Abcam, UK. Antibodies against α-tubulin 
(mouse), monoclonal anti-α smooth muscle actin (SMαA) (Clone 1A4, A5228) and 
GFP (G6539) were from Sigma. Antibody against H3K9me3 (mouse, 05-1250) was 
from Millipore. All secondary antibodies were from Dako, Denmark. Other materials 
used in this study were purchased from Sigma unless specifically indicated.  
 
ES cell culture and smooth muscle cell (SMC) differentiation. Detailed protocols for 
mouse embryonic stem cells (mESCs) (ES-D3 cell line, CRL-1934; ATCC, Manassas, 
USA) culture and SMC differentiation were described in our previous studies
1-9
. 
Briefly, undifferentiated ES cells were dissociated into single cells and seeded onto 
collagen I/IV (5μg/ml)-coated flasks or plates in differentiation medium [DM, MEM 
alpha medium (Gibco) supplemented with 10% FBS, 0.05mM 2-mercaptoethanol, 
100 U/ml penicillin, and 100 μg/ml streptomycin] for 2 to 8 days prior to further 
treatment. The medium was refreshed every other day. For PDGF-BB or TGF-β 
treatment, the pre-differentiated ES cells (day 2~3) were cultured in serum-free basal 
medium (MEM alpha medium supplemented with 1% BSA, 10ng/ml insulin, 100 
U/ml penicillin, and 100 μg/ml streptomycin) for 1hour, followed by the addition of 
different amounts of PDGF-BB or TGF-β and further incubation for 12 or 3 hours, 
respectively. In some specific experiments, cells were treated with actinomycin D in 
DMSO (1µg/ml) for 6 hours in the absence or presence of 2.5ng/ml PDGF-BB or 
1ng/ml TGF-β before harvesting for gene expression analysis. 
 
AdSca-1+ cell isolation and differentiation. Detailed protocols for mouse adventitia 
stem cell antigen 1-positive (AdSca-1+) cell isolation and culture were described in 
our previous studies
2, 10
. Briefly, thoracic arties were harvested and the periadventitial 
fat was carefully removed. Arties were rinsed with PBS and pre-digested for 10~15 
minutes in a digestion solution containing 1mg/ml collagenase (Sigma, C0130-1G). 
Adventitia layer was carefully peeled off from media layer under stereo microscope, 
and cut into small pieces, followed by second digestion in a solution containing 3 
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mg/ml of collagenase and 500 µg/ml elastase at 37ºC for 2-2.5 hours on the shaker, 
vortexing every 20-30 min. Digested cell suspension was collected and filtered 
through a 70µm BD Falcon® cell strainer to obtain single cells. Cells isolated from 
8~10 mice were pooled together and sorted using the Anti-Sca-1 MicroBead Kit 
(MACS Miltenyi Biotec). Freshly isolated AdSca-1+ cells were induced to SMCs in 
the SMC differentiation medium containing DMEM, 10% FBS, 0.05mM 2-
mercaptoethanol, 100 U/ml penicillin, 100 μg/ml streptomycin and 5ng/ml TGF-β for 
2 to 6 days prior to further treatment. The medium was refreshed every other day. 
Immunoblotting. Cells were harvested and lysed in lysis buffer (50mM Tris-Cl pH 7.5, 
150mM NaCl, 1 mM EDTA pH 8.0) supplemented with protease inhibitors and 0.5% 
Triton and sonicated to obtain whole cell lysate. 40 μg of protein was separated by 
SDS-PAGE with 4%~20% Tris-Glycine gel (Invitrogen, Carlsbad, CA, USA) and 
subjected to standard Western blot analysis. In some experiments, the blots were 
subjected to densitometric analysis with Image J software. Relative protein expression 
level was defined as the ratio of target protein expression level to α-tubulin expression 
level with that of the control sample set as 1.0. 
 
Real time quantitative PCR (RT-qPCR) for mRNA and microRNAs. Real-time 
quantitative PCR (RT-qPCR) was performed as previously described
11
. Briefly, total 
RNA containing small RNAs (microRNAs) was extracted from cells using 
mirVana™ Protein and RNA Isolation System™ Kit (Applied Biosystems, Ambion 
Inc) or TRI reagent (Sigma) according to the manufacturer's instructions. Reverse 
transcription for long RNA was performed using an Improm-IITM RT kit (Promega, 
Madison, WI, USA) with RNase inhibitor (Promega), and Random primers (Promega). 
The NCode™ VILO™ miRNA cDNA Synthesis Kit (Invitrogen, A11193-051) was 
used to synthesise poly (A) tails of all the miRNAs followed by cDNA synthesis from 
the tailed population in a single reaction. The resultant cDNA was diluted to a 
working concentration of 5ng/μl and stored at -20ºC. Primers were designed using 
Primer Express software (Applied Biosystems) and the sequence for each primer was 
shown in supplementary Table I. NCode™ EXPRESS SYBR® GreenER™ qPCR 
SuperMix Universal was used in miRNA RT-qPCR. Relative mRNA or microRNA 
expression level was defined as the ratio of target gene expression level or microRNA 
expression level to 18S or U6snRNA expression level, respectively, with that of the 
control sample set as 1.0.  
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Generation of miR-22 overexpressing ES cells. Approximate 606bps of genomic 
fragment containing mmu-miR-22 precursor (95bps) and its flanking sequence 
(256bps and 261bps, respectively) was amplified by PCR with specific primer set as 
shown in Table I from differentiating stem cells, and cloned into Hpa I/Xho I sites of 
the pLL3.7-GFP (Addgene, Plasmid 11795) expression vector, designated as pLL3.7-
GFP-miR-22. All the vectors were verified by DNA sequencing, and the vectors with 
correct sequence were further amplified and used to produce lentiviral particles. 
Briefly, 293T cells were transfected with the control (pLL3.7-GFP) or miR-22 
(pLL3.7-GFP-miR-22) plasmid and the packaging plasmids, pMDLg/pRRE (Addgene, 
12251), pRSV-Rev (Addgene, 12253) and pMD2.G (Addgene, 12259) using 
TurboFect Transfection Reagent (Thermo Fisher Scientific Inc.) according to the 
manufacturer's instructions. The supernatant containing the lentivirus was harvested 
48h later, filtered, aliquoted and stored at –80°C. For lentiviral infection, ES cells 
were plated 24 hours prior to infection in T25 flasks at 37°C. One millilitre of 
respective lentiviral particles were added with 10μg/ml hexadimethrine bromide 
(H9268; Sigma). Viral constructs were incubated 24 hours with the cells before the 
media was replaced with complete media. Cells were culture for further 2~3 days, and 
GFP-positive cells were sorted out and cultured in ES cell culture medium for 2~3 
passages before using. 
 
In vitro/vivo SMC differentiation of miR-22 over-expressing ES cells and 
immunofluorescent staining for sections. Control (pLL3.7-GFP) or miR-22 over-
expression (pLL3.7-GFP-miR-22) ES cells were induced to differentiate into SMCs 
as described above. The procedures for in vivo SMC differentiation were similar to 
that as described in our previous study
1, 2
. Briefly, control or miR-22over-expression 
ES cells (106 in 50µl) were mixed with 50µl of Matrigel (Becton Dickinson Labware) 
and PDGF-BB (100ng/ml) at 4°C, and subcutaneously injected into C57BL/6J mice. 
After 10~13 days, mice were sacrificed and the implants (Matrigel plugs) were 
harvested and frozen in liquid nitrogen for future using. Half of each Matrigel plug 
will be sectioned for detection of cell markers and rests were lysed and extracted total 
RNA to examine related gene expression levels, respectively. All animal experiments 
were performed according to protocols approved by the Institutional Committee for 
Use and Care of Laboratory Animals.  
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For immunofluorescent staining, sections were cut at 8 µm for optimum cutting 
temperature compound–embedded Matrigel implants, every 40 µm along the 
longitudinal axis of Matrigel plugs, and numbered. Given numbered sections (for 
instance, sections 5, 15 and 25) were subjected to immunohistological analyses with 
respective antibody. Briefly, frozen sections were air-dried for at least 30 minutes, 
followed by fixed in cold acetone for 15 minutes. The sections were then rinsed in 
PBS and blocked with 5% BSA in PBS (Sigma) for 1 hr at room temperature in a 
humid chamber. The incubation with primary antibodies (SM-MHC and GFP) or IgG 
controls diluted in blocking buffer was performed in a cold room (4°C) overnight. 
Followed by incubation with appropriate FITC or TRITC conjugated secondary 
antibodies, sections were then incubated with DAPI (1:1000, Sigma) for 5 minutes. 
Images were assessed with Axioplan 2 imaging microscope with Plan-NEOFLUAR 
20×, NA 0.5, objective lenses, AxioCam camera, and Axiovision software (all Carl 
Zeiss MicroImaging, Inc.) at room temperature, and were processed with Photoshop 
software (Adobe). The percentage of GFP-labelled SM-MHC-positive cells with clear 
cell body and strong fluorescence signal per field were counted by two well-trained 
independent investigators blinded to the treatments, from four random high power 
fields (200x) in each section, three sections from each implant and four implants for 
each group. 
microRNA and plasmids transfection. Either miRNAs inhibitors or precursors and 
miRNA negative controls (30nM) were transfected into differentiating ES cells using 
siPORTTM NeoFXTM transfection agent (Ambion, Applied Biosystems) according 
to the manufacturer's instructions. Transfected cells were plated into flasks or plates 
coated with 5μg/ml of collagen and cultured for 48~72 hours in the SMC 
differentiation medium to allow SMC differentiation. All miRNAs inhibitors or 
precursors and respective negative controls were purchased from Ambion. Mouse full 
length of MECP2 gene was amplified by RT-PCR from ES cells with primer set as 
shown in Table I and cloned into Mlu I/Xba I sites of the pCMV5 expression vector, 
designated as pCMV5-MECP2. All the vectors were verified by DNA sequencing, 
and the vectors with correct sequence were further amplified and used in the related 
experiments. Control (pCMV5) and MECP2 overexpression (pCMV5-MECP2) 
plasmids were transfected into differentiating ES cells using TurboFect Transfection 
Reagent (Thermo Fisher Scientific Inc.) according to the manufacturer's instructions. 
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Flow cytometry analysis. Differentiated cells were dissociated into single cells by 
trypsin-EDTA (Gibco, Invitrogen) and subjected to flow cytometry analyses using 
antibodies against GFP or SMαA as described in our previous studies1, 9.    
 
MECP2 3’UTR clone and miR-22 binding sites mutation. Reporter vector harboring 
sequences of the murine MECP2 was created using cDNA from ES cells. Three 
fragments (1567-2698, 4142-4968 and 8173-9137) containing partial 3’-flanking 
untranslation region (3’UTR) of murine MECP2 gene (NM_001081979) were 
amplified by PCR with primer sets shown in Table I and cloned into the Mlu I and 
Sac I sites of the pmiR-reporter-basic vector (Ambion, Applied Biosystems), 
designated as pmiR-Luc-MECP2-A (harboring miR-22 binding sites 1 1577~1616) 
and 2 (2797~2836)), B (harboring binding site 3, 4537~4576) and C (containing 
binding site 4, 8347~8386), respectively (Figure VIIA). miR-22 binding site 1, 2 
mutation alone or combination in reporter A or C were introduced into respective 
pmiR-Luc-MECP2 reporter by using QuikChange™ site-directed mutagenesis kit 
(Agilent Technologies) according to the manufacturer's instructions. The resultant 
vectors were designated as pmiR-Luc-MECP2-A-bs2mu, pmiR-Luc-MECP2-A-
bs1/2mu, and pmiR-Luc-MECP2-C-bsmu mutants, respectively. All mutants were 
verified by DNA sequencing. 
 
Transient transfection and luciferase assay. Luciferase assay for WT and mutated 
MECP2 3’UTR reporters were conducted as previously study11. Briefly, day 2~4 
differentiating ES cells were co-transfected with individual reporter genes (pmiR-
Luc-MECP2-A/B/C, pmiR-Luc-MECP2-A-bs2mu, pmiR-Luc-MECP2-A-bs1/2mu, 
or pmiR-Luc-MECP2-C-bsmu, 0.15 μg/2.5 x 104 cells) and control or miR-22 
precursor (30nM) using siIMPORTER transfection reagents (Millipore), according to 
the manufacturer’s instructions. Gene promoter luciferase activity assays were 
performed as previously described
4, 5, 8
. Briefly, differentiating cells were co-
transfected with respective gene promoter reporter (pGL3-Luc-genes, 0.15 μg/2.5 x 
104 cells) and control (pCMV5, 0.20 μg/2.5 x 104 cells) or MECP2 over-expression 
(pCMV5-MECP2, 0.20 μg/2.5 x 104 cells) plasmid, respectively, using TurboFect 
Transfection Reagent (Thermo Fisher Scientific Inc.) according to the manufacturer’s 
instructions. The gene promoter reporters used in this study were generated in our 
previous studies, eg. pGL3-Luc-SMαA7, pGL3-Luc-SM22α7, pGL3-Luc-SMαA-
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SRFmu
1
, pGL3-Luc-SM22α-SRFmu1, pGL3-Luc-SRF1, pGL3-Luc-MEF2c1, pGL3-
Luc-Myocardin
1
, and pGL3-Luc-HDAC7
5, 7
. pGL3-Luc-Nox4 was purchased from 
Generay Biotechnology (Shanghai, China). pShuttle2-LacZ (0.20μg/2.5 x 104 cells) 
was included in all transfection assays as internal control. Luciferase and β-
galactosidase activities were detected 48 hours after transfection using a standard 
protocol. Relative luciferase unit (RLU) was defined as the ratio of Luciferase versus 
β-galactosidase activity with that of the control (set as 1.0).  
MECP2 knockdown by siRNAs. A pool of small interfering RNAs (siRNAs) for 
MECP2 (MISSION® esiRNA, esiRNA targeting mouse Mecp2, EMU085661-20UG) 
and MISSION® siRNA Universal Negative Control #1 (SIC001-10NMOL) were 
purchased from Sigma. ES cells were cultured on collagen IV-coated 6-well plates for 
3~4 days, and 6 μl of 10μM siRNA (final concentration of siRNAs: 60nM) was 
introduced with siIMPORTER transfection reagents (Millipore) according to the 
protocol provided. Cells were harvested at 48 or 72 hours after transfection and real-
time RT-PCR analyses were performed.  
 
Chromatin immunoprecipitation (ChIP) assays.  The ChIP assays were performed as 
previously described
1-3, 11
. Briefly, differentiating ES cells transfected with control 
(pCMV5) or MECP2 over-expression (pCMV5-MECP2) plasmids were treated with 
1% (v/v) formaldehyde at room temperature for 10 min and then quenched with 
glycine at room temperature. The medium was removed, cells were harvested and 
sonicated. The sheared samples were diluted into 1 ml immunoprecipitation buffer, 
and immunoprecipitations were conducted with antibodies raised against MECP2 
(goat, sc-5755; rabbit, ab2828), SRF (rabbit, G-20, sc-335), or H3K9me3 (mouse, 05-
1250), respectively. Immunoprecipitation complex was pulled-down using protein-G- 
Dynabeads. Equal amount (2µg/immunoprecipitation) of normal goat, rabbit or mouse 
IgG was used as control. The immunoprecipitates were eluted from the beads using 
100 μl elution buffer, and immunoprecipitaed DNA was extracted, purified, and then 
used to amplify target DNA sequences by RT-qPCR using specific primers (Table I). 
Promoter DNA enrichment with specific antibody was calculated using percent input 
method with that of the IgG control set as 1.0. The relative level of promoter DNA 
enrichment was defined as the ratio of promoter DNA enrichments in the samples 
with treatment(s) (pCMV5-MECP2) to the control samples (pCMV5) with that of the 
control sample set as 1.0. PCR amplification of the adjacent promoter regions or 
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regions lacking of SRF binding sites (without CArG region) were included as 
additional control for specific promoter DNA enrichment. The data was obtained from 
three to four independent experiments.   
 
Statistical analysis. Data were expressed as mean±SEM and analyzed using a two-
tailed student’s t-test for two-group comparison or one-way ANOVA followed by 
Tukey’s HSD multiple comparison post-hoc test for comparing different groups. A 
value of P < 0.05 was considered as statistically significant. 
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Supplementary table I: Primer sets used in the present study 
 
Gene 
names 
Forward (5’-3’) Reverse (5’-3’) Application 
U6 snoRNA gatgacacgcaaattcgtg miRNA universal reverse primer 
(Invitrogen, A11193-051) 
Real-time RT-PCR 
(RT-qPCR) 
18s CCCAGTAAGTGCGGGTCATAA CCGAGGGCCTCACTAAACC RT-qPCR 
miR-22 
(mu/hu) 
AAGCTGCCAGTTGAAGAACTGT  miRNA universal reverse primer 
(Invitrogen, A11193-051) 
RT-qPCR 
miR-22 
precursor (mu) 
ACCTGGCTGAGCCGCAGTAG AGGGGCAGAGGGCAACAGTTC RT-qPCR to detect 
miR-22 precursor RNA 
miR-22 
Primary (mu) 
AAAGGGGCACAAAGCAAGTG CAGGAAAGCTGGGTGACAGG RT-qPCR to detect 
miR-22 primary RNA 
SMαA  TCCTGACGCTGAAGTATCCGAT GGCCACACGAAGCTCGTTATAG RT-qPCR 
SM22α GAT ATG GCA GCA GTG CAG AG AGT TGG CTG TCT GTG AAG TC RT-qPCR 
h1-Calponin  GGT CCT GCC TAC GGC TTG TC  TCG CAA AGA ATG ATC CCG TC RT-qPCR 
SM-myh11  AAG CAG CCA GCA TCA AGG AG AGC TCT GCC ATG TCC TCC AC RT-qPCR 
SRF CCTACCAGGTGTCGGAATCTGA TCTGGATTGTGGAGGTGGTACC RT-qPCR 
Myocd TCAATGAGAAGATCGCTCTCCG GTCATCCTCAAAGGCGAATGC RT-qPCR 
MEF2C AAGCCAAATCTCCTCCCCCTAT TGATTCACTGATGGCATCGTGT RT-qPCR 
MECP2 GGCTGTGGTAAAACCCGTCCG GGCTTGTCTCTGAGGCCCTGGA RT-qPCR 
Nox4 ATTTGCCTGGAAGAACCCAAG CATCGGTAAAGTCTCTCCGCA RT-qPCR 
HDAC7 CCCAGTGTGCTCTACATTTCCC CACGTTGACATTGAAGCCCTC RT-qPCR 
Nrf3 TGCCAGATGCAGGCGGATGC TTGCCTGGGCTGACACCCCT RT-qPCR 
Cbx3 GAACGAATAATCGGCGCCA ATGTTCGCCTCCTTTGCCA RT-qPCR 
hnRNPA1 TTCATCCAGTCAGAGAGGTCGC TGAAGTTCCCTCCTCGACCAA RT-qPCR 
hnRNPA2B1 CTGCAAGCAAAAGATCAAGAGG GCTCAACTACCCTGCCATCAA RT-qPCR 
Pla2g7 CACTGGCAAGACACATCTTC ATCAGATCTGTACAACCGAC RT-qPCR 
SMαA-P1 CATAACGAGCTGAGCTGCCTC CCAAACAAGGAGCAAAGACG CHIP assay (with 
CArG region) 
SMαA-P2 GATCAGAGCAAGGGGCTATA CTACTTACCCTGACAGCGAC CHIP assay (without 
CArG region)  
SM22α-P1 GCAGGTTCCTTTGTCGGGCCA CTGCTTGGCTCACCACCCCG CHIP assay (with 
CArG region) 
SM22α-P2 CTTTAAACCCCTCACCCAGC ATGACTTGCACTTACAAGG CHIP assay (without 
CArG region)  
SRF-
P_F1/R1 
GGCTGGGCCCTCCCCCATTT TGGCTGGTTTGCTGGTTTGGCA CHIP assay 
SRF-
P_F3/R3 
TCAGGCCTGTGCTTTAGCCTCG GATGGGGGCAGGGCGGAAAG CHIP assay 
(Adjacent region) 
Myocd-
P_F2/R2 
ACGTGGGACCCTGTCACCCC GGATTCGGTGGCCTGGGCAAG CHIP assay  
Myocd-
P_F3/R3 
CGGGAGTTGCAAGCCAACCCA TCCCCAGCTTACTGCAGGGCT CHIP assay 
(Adjacent region) 
Pla2g7-p2 GGGCTCCTAGCTGGCACGTC TCTCCACCCCAACCCACCCC CHIP assay  
Pla2g7-p10 GGGATGGGCACAGCTCGTCG CTCGACCCTCCCCTCCTCCG CHIP assay 
(Adjacent region) 
Nox4-p CCATTGCACACTCCTCACCT GAAGCTCAGATTCCCTCTAGGA CHIP assay  
Nox4-p-adj TGGACCATGGCTTCAGTGTT CAGCACACCGGGCTTTGAA CHIP assay 
(Adjacent region) 
HDAC7-p CACTGGCAGGTGAATCCTGT GGACAGAGGATTGTGCAGGT CHIP assay  
HDAC7-p-
adj 
TCCAGGACACTCAAGAAGGG GCCTGGGGTGTCCCTTTATC CHIP assay 
(Adjacent region) 
mus miR-22 
precursor 
GTGCTCGTTAACCTGCCCTTTGAATG
CCGAAG 
GTGCTCCTCGAGGGGGAGGTGGAG
TCACCTAT 
pLL3.7-GFP-miR-
22 clone 
Mus MECP2 ctcgtcACGCGTttggccgccgctgccgccac ctccac TCTAGA tcagctaactctctcggtcacgg pCMV5-MECP2 
clone 
pmiR-Luc-
MECP2-A 
GCTGTCACGCGTGCGGATTGCAAAG
CAAACCAACA 
GTCGACGAGCTCACCTGGCACTGGC
AATGGGA 
MECP2 3’UTR 
reporter-A clone 
pmiR-Luc-
MECP2-B 
CTACTGACGCGTCCCAACCTGCCCCA
TGCACTC 
TCCTCAGAGCTCTGCACACCAAGGG
CAGCAGTT 
MECP2 3’UTR 
reporter-B clone 
pmiR-Luc-
MECP2-C 
CTGCTGACGCGTCCGGCATGAGATG
GGGGCAGA 
CTGTGTGAGCTCTCCTTTCCCTCCTG
GCACTCCTA 
MECP2 3’UTR 
reporter-C clone 
pmiR-Luc-
MECP2-A-
bs2mu 
TCTTCTGTTCCATTTGAAGGCAGTGC
TGAA CC 
GGTTCAGCACTGCCTTCAAATGGAACAG
AAGA 
miR-22 binding site 2 
mutation in reporter-A 
 3 
pmiR-Luc-
MECP2-A-
bs1/2mu 
CCAACAAGAATAAATTTGAAGGTTG
TCTCTTCTCC 
TCTTCTGTTCCATTTGAAGGCAGTG
CTGAA CC 
miR22 binding site 1 
and 2 combinational 
mutation in reporter-A 
pmiR-Luc-
MECP2-C-
bsmu 
ATGTTTCTGTTTGAAGGGACAATGGA
GTGC 
GCACTCCATTGTCCCTTCAAACAGA
AACAT 
miR-22 binding site 
mutation in reporter-C 
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Supplementary  Figures and Legends: 
 
Figure I. Gene expression levels of SMC-specific genes were significantly up-
regulated during stem cell differentiation toward SMCs.  
 
Undifferentiated ES cells were plated into flasks coated with 5µg/ml of collagen and 
cultured in SMC differentiation medium to allow for SMC differentiation. Total RNA 
from undifferentiated ES cells (d0) or differentiating ES cells at day 2, 4, 6 and 8 were 
harvested and subjected to RT-qPCR analyses with primers specific for SMαA and 
SM-Myh11, respectively. The data presented here are mean±S.E.M. of three 
independent experiments. Significant difference from control (day 0), *P<0.05.  
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Figure II. Quantitative analyses of protein relative expression levels.  
 
The blots were subjected to densitometric analysis with Image J software. Panel A, B, 
C and D refer to figure 1B, 1C, 2C and 3B, respectively. *p<0.05 (versus respective 
control). 
 
Figure III. Modulation of miR-22 expression in differentiating ES cells regulates 
SMC transcription factors.  
 
miR-22 over-expression (A) increases, while inhibition (B) reduces SRF and 
myocardin expressions. Total RNA and protein were harvested as described in Figure 
1, and subjected to RT-qPCR analyses. The data presented here are representative or 
mean±S.E.M. of three independent experiments. *P<0.05. 
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Figure IV. Generation of miRNA-22 overexpressing ES cells and differentiation 
towards SMCs. 
 
(A) Sorted ES cells were GFP-positive. (B) miR-22 was significantly increased during 
SMC differentiation. *P<0.05 (versus day 0), #P<0.05 (pLL3.7-GFP-miR-22 versus 
pLL3.7-GFP). (C) More SMCs were differentiated from miR-22 overexpressing ES 
cells. Parental ES cells (control ES cells), control (pLL3.7-GFP) and miR-22 over-
expressing (pLL3.7-GFP-miR-22) ES cells were induced to differentiate into SMCs 
for 8 days. Cells were harvested and subjected to flow cytometry analyses using 
SMαA antibody. Undifferentiated cells (Day 0) were included as differentiation 
control. Representatives of flow cytometry histogram or mean±S.E.M. of three 
independent experiments were presented here.  
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Figure V. miR-22 promotes SMC differentiation in vivo.  
 
Matrigel plugs implanted with control (pLL3.7-GFP) or miR-22 over-expression 
(pLL3.7-GFP-miR-22) ES cells were harvested, sectioned and subjected to 
immunofluorescence staining using antibodies against GFP and SM-MHC. 
Representative images (A) and quantitative data (B) of the percentage of SM-MHC-
positive cells were presented here, respectively. Note: cells with green fluorescence 
signal indicate GFP-positive cells (implanted cells) within Matrigel plugs. The 
percentage of GFP-labelled SM-MHC-positive cells with clear cell body and strong 
fluorescence signal per field were examined by two well-trained independent 
investigators blinded to the treatments, from four random high power fields (200x) in 
each section, three sections from each implant and four implants for each group, 
*p<0.05. (C) Gene expression levels within Matrigel implants. Total RNA samples 
were extracted from partial Matrigel implants and subjected to RT-qPCR analysis. 
The data presented here are mean±S.E.M. of four Matrigel implants. *P<0.05. 
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Figure VI. Functional importance of miR-22 in adventitia stem/progenitor cell 
differentiation towards SMCs.  
 
(A) Induction of miR-22 during SMC differentiation from AdSca-1
+
 cells. Day 0 
samples were freshly isolated AdSca-1
+
 cells and served as undifferentiated control. 
(B) miR-22 overexpression up-regulated SMC marker expressions. Cultured AdSca-
1
+
 cells were transfected with miR-22 precursor or negative control, and cultured in 
SMC differentiation medium for 48~72 hours. (C) miR-22 inhibition impairs SMC 
marker expressions. Day 2 differentiating AdSca-1
+
 cells were transfected with miR-
22 inhibitor or negative control, and cultured in SMC differentiation medium for 48 
hours. Total RNA was harvested and subjected to RT-qPCR analyses. The data 
presented here are mean±S.E.M. of three independent experiments. *P<0.05. 
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Figure VII. Schematic illustration of MECP2 3’UTR regions and pmiR-Luc-
MECP2 reporters (wild type and miR-22 binding site mutants) 
 
(A) Positions for miR-22 bindings sites (BS1~4, black rectangles) within MECP2 
gene, and the individual MECP2 3’UTR segment for respective pmiR-Luc-MECP2 
reporter A, B and C are depicted in this illustration. (B) The four miR-22 binding sites 
were predicted by using Targetscan (A) (www.targetscan.org). The MECP2 3’UTR 
sequence flanking the respective miR-22 binding sites (wild type and related mutants), 
and miR-22 sequence were illustrated here, respectively.  
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Figure VIII. MECP2 over-expression abolished gene expression induced by miR-
22. 
 
Day 2 differentiating control (pLL3.7-GFP) and miR-22 over-expressing (pLL3.7-
GFP-miR-22) ES cells were transfected with respective control (pCMV5) and 
MECP2 over-expression (pCMV5-MECP2) plasmids, and cultured in SMC 
differentiation medium for further 48 to 72 hrs. Total RNAs were harvested and 
subjected to RT-qPCR analyses. The data presented here are mean±S.E.M. of three 
independent experiments.  
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Figure IX. SRF binding site is required for MECP2 mediated SMC gene 
expression.  
 
 
(A) SRF binding site mutation abolished SMC differentiation gene promoter activity 
induced by MECP2 overexpression. (B) CHIP assay showed no direct binding of 
MECP2 to the promoter regions of SMC differentiation genes. (C) the binding 
capacity of SRF to the promoter regions of SMC differentiation genes were not 
affected by MECP2 over-expression. ChIP assays were performed using antibodies 
against MECP2 and SRF, as well as its respective normal IgG, as described in online 
supplemental data. PCR amplifications of the non-CArG regions were included as 
additional control for specific promoter DNA enrichment.  The data presented here 
are mean±S.E.M. of three independent experiments. *P<0.05 (vs. control). 
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Figure X. Nox4 and HDAC7 gene expressions were transcriptionally regulated 
by MECP2. 
 
(A) Promoter activities of Nox4 and HDAC7 genes were inhibited by MECP2 over-
expression. Day 2~3 differentiating ES cells were transfected with luciferase reporter 
plasmids pGL3-Nox4-Luc or pGL3-HDAC7-Luc (0.15μg/2.5×104 cells) together with 
pCMV5 or pCMV5-MECP2 (0.2μg/2.5×104 cells). pShuttle-LacZ (0.2μg/2.5×104 cells) was 
included as control. Luciferase and β-galactosidase activity assays were detected 48 hours 
after transfection. The data presented here are mean±S.E.M. of four independent experiments. 
*P<0.05 (vs. control). (B) MECP2 binds directly to the promoter regions of Nox4 and 
HDAC7 genes. ChIP assays were performed using antibody against MECP2 or normal IgG, 
respectively. PCR amplifications of the adjacent regions were included as additional control 
for specific promoter DNA enrichment. The data presented here are mean±S.E.M. of four 
independent experiments. *P<0.05 (vs. control). 
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Figure XI. miR-22 over-expression decreased the H3K9 methylation within SRF, 
Myocd and Pla2g7 gene promoters. 
 
ChIP assays were performed using antibody against H3K9me3 or normal mouse IgG, 
respectively, as described previously. The enrichment of H3K9me3 within the promoter 
regions of SMαA (A), SM22α (B), SRF (C), myocd (D) and Pla2g7 (E) were examined using 
two pairs of primers specific for regions-of-interest and adjacent regions of individual gene as 
indicated. The data presented here are mean±S.E.M. of three independent experiments. 
*P<0.05 (vs. control). 
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Figure XII. PDGF-BB and TGF-β up-regulate miR-22 through a transcriptional 
mechanism. 
 
 
(A and B) Both PDGF-BB and TGF-β up-regulate miR-22 expression. Day 2~3 
differentiating ES cells were incubated with the indicated dose of PDGF-BB (A) and TGF-β 
(B) for 12 hours and 3 hours, respectively. (C and D) Both miR-22 precursor and primary 
RNA levels were up-regulated by PDGF-BB and TGF-β treatments. Day 2~3 differentiating 
ES cells were incubated with PDGF-BB (C, 2.5ng/ml) and TGF-β (D, 1ng/ml) for 12 hours 
and 3 hours, respectively. (E and F) Actinomycin D abolished the effect of PDGF-BB and 
TGF-β treatments on the expression levels of miR-22. Total RNAs were harvested and 
subjected to RT-qPCR analyses with respective primers. The data presented here are 
mean±S.E.M. of three independent experiments. *P<0.05 (versus control/DMSO), #P<0.05 
(ActD versus DMSO in the presence of PDGF-BB/TGF-β). 
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Figure XIII. Proposed model of miRNAs-mediate SMC differentiation.  
 
Abbreviations: ESC, embryonic stem cell; SMC, smooth muscle cell; miR-22, microRNA-
22; miR-34a; microRNA-34a; SRF, serum response factor; pSRF, phosphorylated SRF; 
Myocd, myocardin; MECP2, methyl CpG binding protein 2; H3K9me3, histone H3 trimethyl 
Lys9; Nox4, NADPH oxidase 4; Pla2g7, phospholipase A2, group VII; HDAC7, histone 
deacetylase 7; Ros, reactive oxygen species; PDGF-BB, platelet-derived growth factor; TGF-
β, transforming growth factor beta; MEF2c, myocyte-specific enhancer factor 2C; SirT1, 
NAD-dependent deacetylase sirtuin-1. 
 
 
 
 
 
 
 
